Stellate Ganglion Block in Patients With Advanced Primary Parkinson's Disease: a Small, Open, Randomized Controlled Clinical Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

At present, there are no reports on the application of stellate ganglion block in the treatment of Parkinson's disease patients at home and abroad. Based on the preliminary clinical observation, this project intends to apply stellate ganglion block in the treatment of patients with intermediate and advanced Parkinson's disease through an open, randomized controlled small sample clinical study. To determine whether stellate ganglion block can effectively improve motor symptoms and non-motor symptoms in patients with primary advanced Parkinson's disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 85
Healthy Volunteers: t
View:

⁃ Patients with Parkinson's disease who met the diagnostic criteria for MDS as probable PD or confirmed PD in 2016

‣ Age 40-85;

‣ Patients with Parkinson's disease who met the diagnostic criteria of MDS as probable PD or confirmed PD in 2016;

‣ The patient or his/her legal guardian agrees to participate in the study and signs the informed consent;

‣ Hoehn-yahr (H\&Y) 2.5 \

• 5;

Locations
Other Locations
China
Zhujiang Hospiatal
RECRUITING
Guangzhou
Contact Information
Primary
Xiaoya Gao, doctor
gaoxy23@126.com
86-18680282869
Backup
Kaitao Wang, graduate
137783032@qq.com
86-18775317530
Time Frame
Start Date: 2023-07-28
Estimated Completion Date: 2024-06-30
Participants
Target number of participants: 38
Treatments
Experimental: Parkinson's disease group
Diagnostic criteria: Patients with Parkinson's disease who met the diagnostic criteria for MDS as probable PD or confirmed PD in 2016~Inclusion criteria:~1. Age 40-85;~2. Patients with Parkinson's disease who met the diagnostic criteria of MDS as probable PD or confirmed PD in 2016;~3. The patient or his/her legal guardian agrees to participate in the study and signs the informed consent;~4. Hoehn-yahr (H\&Y) 3 \~ 5;
Experimental: Non-parkinson's disease group
Exclusion criteria:~1. Allergic to local anesthetic drugs;~2. Unable to cooperate with motor or non-motor function monitoring;~3. Patients with Parkinson's superposition syndrome, such as cortical basal ganglia degeneration, lewy body dementia, multisystem atrophy and progressive supranuclear palsy, were excluded; Patients with secondary Parkinson's disease, such as vascular Parkinson's disease, drug toxicity or traumatic Parkinson's disease;~4. Refuse to sign the consent form.
Sponsors
Leads: Zhujiang Hospital

This content was sourced from clinicaltrials.gov